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Abstract In vivo 1H MR spectroscopy allows the non
invasive characterization of brain metabolites and it has
been used for studying brain metabolic changes in a wide
range of neurodegenerative diseases. The prion diseases
form a group of fatal neurodegenerative diseases, also
described as transmissible spongiform encephalopathies.
The mechanism by which prions elicit brain damage
remains unclear and therefore different transgenic mouse
models of prion disease were created. We performed an
in vivo longitudinal 1H MR spectroscopy study at 14.1 T
with the aim to measure the neurochemical profile of Prnp
-/- and PrPD32-121 mice in the hippocampus and cerebellum.
Using high-field MR spectroscopy we were able to analyze
in details the in vivo brain metabolites in Prnp -/- and
PrPD32-121 mice. An increase of myo-inositol, glutamate
and lactate concentrations with a decrease of N-acetylas-
partate concentrations were observed providing additional
information to the previous measurements.
Keywords In vivo proton magnetic resonance
spectroscopy  Brain metabolites  Mouse brain  Prion
disease
Introduction
Prion diseases form a group of fatal neurodegenerative
diseases, also described as transmissible spongiform
encephalopathies (TSEs), which are caused by abnormal
conformational isomers (PrPSc) of the host-encoded prion
proteins (PrPc) [1]. PrPc is expressed in all vertebrate
species examined to date, mainly in the brain but also in
many other tissues at lower levels [2]. The nature of the
prion has been a longstanding enigma. Both, the physio-
logical function of PrPc and the molecular pathways lead-
ing to neurodegeneration in prion disease remain unknown.
In addition, the mechanism by which prions elicit brain
damage and the relative contributions of PrPSc accumula-
tion and PrPc depletion to the prion replication remains
unclear [3].
Consequently, different animal models were created to
study the role of the PrPc. Among these models, knockout
mouse models were crucial in elucidating the precursor-
product relationship between PrPc and PrPSc. Among these
models, the mice lacking prion protein (Prnp -/-) developed
normally and no severe pathologies were observed [4]. In
contrast, mice expressing PrP which lacks defined domains
(PrPD32-121) suffer from ataxia, astrogliosis and cerebellar
granule cell loss [5]. Since the lack of PrPc itself did not
induce an obvious phenotype, mice expressing PrP, which
lacks defined domains, may allow the identification of
functionally relevant domains within PrPc. Generally, prion
diseases in humans (also called Creutzfeldt–Jakob disease)
are characterized by neurodegeneration with primary signs
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of impaired cognitive functions and ataxia [6]. Moreover,
the neuropathological features are spongiform degeneration
of the brain accompanied by neuronal loss and astrocytic
activation (gliosis) [6]. These findings accentuate the need
for a non-invasive and longitudinal investigation technique
which could bring additional information.
Magnetic resonance imaging (MRI) and magnetic reso-
nance spectroscopy (MRS) became in the last decades
powerful and reliable diagnostic tools allowing the non-in-
vasive characterization of brain metabolites together with
the study of brain metabolites changes in a wide range of
neurodegenerative diseases. In addition, the availability of
high magnetic field strengths (C7 T) combined with the
possibility of acquiring spectra at very short echo time
(\10 ms) have increased the number of in vivo detectable
brain metabolites to about 20 metabolites in animal models
and humans: glucose (Glc), lactate (Lac), creatine (Cr),
phosphocreatine (PCr), alanine (Ala) (markers of energy
metabolism); phosphocholine (PCho), glycerophospho-
choline (GPC), phosphoethanolamine (PE), N-acetylaspar-
tate (NAA), N-acetylaspartylglutamate (NAAG) (markers of
myelination/cell proliferation); glutamate (Glu), glutamine
(Gln), aspartate (Asp), c-aminobutyrate (GABA), glycine
(Gly) (neurotransmitters and associated metabolites); taurine
(Tau), myo-inositol (Ins) (markers of osmoregulation) and
ascorbate (Asc), glutathione (GSH) (antioxidants). Conse-
quently, the use of in vivo, non-invasive and longitudinal
MR measurements is a promising tool to assess pathogenic
mechanisms, to diagnose and monitor disease progression
and/or effect of treatment, and made a bridge between the
clinical diagnostics and basic research.
Only few reports describe the use of in vivo 1H MRS in
patients with prion disease so far [7–11]. This number is
even smaller for animal models [12–14]. In addition, only a
few metabolites were reported in these studies (mainly
NAA).
To our knowledge, no in vivo MRS study was per-
formed in transgenic mouse models of prion disease.
Therefore, the aim of the present study was to measure the
neurochemical profile of Prnp -/- and PrPD32-121 mice in the
hippocampus and cerebellum at 6 and 12 months of age
using in vivo longitudinal 1H MRS at 14.1 T.
Methods
Animals
Mice lacking prion protein (Prnp -/- mice, n = 6) and mice
expressing PrP which lacks defined domains (PrPD32-121,
n = 6) were created in the laboratory of Prof A. Aguzzi in
Zurich as described in ref [4] and [5], respectively. Six wild
type mice (WT) were used as controls. All the mice used in
this study were of BALB/c strain. In vivo MRI and MRS
experiments were performed longitudinally at 6 and
12 months of age on all the animals (total of 18 mice).
Spontaneously breathing mice were anesthetized during
experiments with 1.3–1.5 % isoflurane in oxygen (Attane,
Minrad, NY, USA) using a nose mask. A stereotaxic system
(bite bar and a pair of ear bars) (Rapid Biomedical, Ger-
many) was used to fix the head. Then the animal was placed
in an in-house-built holder and afterwards placed in the
magnet. The vital signs of the animals were carefully mon-
itored during in vivo measurements to provide a stable
physiological condition. Body temperature was measured
using a rectal thermosensor and maintained at 36.5 ± 0.2 C
by circulating warm water around the animals. Respiration
rate was monitored by a small-animal monitor system (SA
Instruments Inc., New York, NY, USA).
All MRI and MRS experiments were conducted
according to federal and local ethical guidelines and the
protocols were approved by the local regulatory body of
the Canton Vaud, Switzerland.
MRI and MRS Measurements
All data were acquired on a 14.1 T/26 cm system (Magnex
Scientific, Oxford, UK) interfaced to a Varian Direct Drive
console (Palo Alto, CA, USA) and equipped with 12-cm
inner-diameter actively-shielded gradient set with a maxi-
mum gradient of 400 mT/m in 120 ls. A home-built
quadrature coil consisting of two geometrically decoupled
14-mm-diameter single loops was used as radio frequency
(RF) transceiver. Eddy currents were minimized using time-
dependent quantitative eddy-current field mapping [15]. The
static field was shimmed using first- and second order shims
obtained by the echo planar imaging (EPI) version of
FASTMAP [16]. First, T2 weighted images were obtained in
the axial plane using a multislice fast spin echo protocol
with TR/TEeff = 5000/52 ms; echo train length = 8; field-
of-view = 24 mm 9 24 mm; slice thickness = 0.6 mm; 6
averages; 128 9 128 image matrix. Afterwards, 1H MRS
spectra were acquired using the ultra-short-echo time SPE-
CIAL spectroscopy sequence (TE = 2.8 ms, TR = 4 s, 400
scans) [17]. A VOI of 1.3 9 2 9 2.2 mm3 was selected in
the hippocampus and a second VOI of 2 9 2.5 9 2 mm3
was selected in the cerebellum. After first and second order
shimming, the typical linewidth of water resonance at
TE = 2.8 ms was 18–23 Hz. The water signal was sup-
pressed using the VAPOR module containing a series of
seven 25 ms asymmetric variable power RF pulses with
optimized relaxation delays [18]. To improve the signal
localization, three modules of outer volume saturation
(OVS) were interleaved with the water suppression pulses as
described previously [18]. Spectra were collected in blocks
of 16 averages to compensate for the magnetic field drift.
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The blocks were stored separately in the memory and cor-
rected for the relative shift in frequency and potential vari-
ations in phase before summation using an in house matlab
routine.
Metabolite concentrations were estimated using
LCModel (http://s-provencher.com/pages/lcmodel.shtml)
[19], combined with a quantum mechanics simulated basis-
set of metabolites based on the density-matrix formalism,
and using published values of J-coupling constants and
chemical shifts [20]. The following 20 metabolites were
included in the basis-set: Ala, Asp, PCho, Cr, PCr, GABA,
Gln, Glu, GSH, Gly, Ins, Lac, NAA, Tau, Asc, Glc,
NAAG, GPC, Scyllo (scyllo-inositol) and PE. LCModel is
also reporting the sum of selected metabolites like tNAA
(NAA ? NAAG), tCho (PCho ? GPC) and tCr (Cr ?
PCr) but these are not considered as being additional
estimated metabolites. In addition, the spectrum of
macromolecules measured in vivo as described previously
[17, 21–23] was included in the basis-set. Absolute
metabolite concentrations were obtained using unsup-
pressed water signal as an internal reference. The Cramer–
Rao lower bounds were used as a reliability measure of the
metabolite concentration estimates.
All metabolite concentrations are presented as
mean ± SD. Significance for difference was tested using a
two-way repeated measures ANOVA followed by Bon-
feroni post-test (Prism 5, GraphPad, La Jolla, CA, USA).
Probability values of p\ 0.05 were considered statistically
and biologically significant. ANOVA between prion and
WT mice was performed with respect to metabolite in the
neurochemical profile in each brain region with age as
repeated factor.
Results
To evaluate the consistency of our data on WT mice with
prior literature we analyzed the brain regional differences
between hippocampus and cerebellum together with the
age dependency (6 vs 12 months of age). Substantial
regional variations (hippocampus vs cerebellum) were
obtained and were also visually discernible after a careful
inspection of the spectra (Fig. 1): an increase in Tau
(p\ 0.001) peak and lower Ins (p\ 0.05), tCr (p\ 0.05)
signal intensities. These regional differences are similar
with previously published data in another mouse strain, the
C57BL/6 mice [24]. For both brain regions the metabolite
concentrations are very similar at both ages. The only
change with age was found in hippocampus: a decrease in
Ins (p\ 0.05) and tCho (p\ 0.05) concentrations.
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Fig. 1 Up in vivo 1H MRS spectra acquired in the hippocampus and cerebellum of a WT mouse using the SPECIAL sequence, down the
neurochemical profile (mean ± SD) in the hippocampus and cerebellum of 6-month old WT mice
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No visible difference in the T2 weighted images was
observed between the WT and Prnp -/- or PrPD32-121 ani-
mals. The T2 weighted images showed adequate anatomi-
cal contrast and spatial resolution for accurate positioning
of the voxel in hippocampus and cerebellum based on
anatomical landmarks (Fig. 2).
To assess the quality of in vivo 1H MRS data Figs. 1, 2
and 4 show the high quality spectra obtained routinely in
our study. In general, spectra exhibited excellent signal-to-
noise ratio estimated by LCModel as the ratio of the
maximum in the spectrum minus baseline over the analysis
window to twice the root-mean-square residuals (i.e.
19 ± 3 for hippocampus and 26 ± 4 for cerebellum,
Figs. 1 and 2). The VAPOR water suppression provided a
residual water signal intensity below that of NAA and the
quality of signal localization was confirmed by the absence
of contamination with extracerebral lipid peaks at
1.3–1.7 ppm. In our study, FASTMAP shimming resulted
in unsuppressed water signal linewidths of 18–20 Hz for
hippocampus and 20–23 Hz for cerebellum, which leads to
highly resolved spectra. Moreover, notable differences in
metabolite signals were discernible directly from the
spectra (a decrease of NAA and an increase of Ins peaks) as
shown in Figs. 1, 2 and 4.
To determine potential differences between Prnp -/-,
WT and PrPD32-121 mice, the neurochemical profile
(mean ± SD) measured at 12 months in the hippocampus
and cerebellum is shown in Fig. 3. We were able to reliably
estimate the concentration of 19 brain metabolite with
CRLBs between 1 and 20 %. The signal of scyllo-inositol
was included in the basis-set but its concentration was not
reliably estimated in the majority of the spectra
(CRLBs[ 55 %).
The PrPD32-121 mice showed no significant changes in
the hippocampus at 6 months; however an increase of Ins
(15 %, p\ 0.05) and Glu (20 %, p\ 0.05) was found in
the cerebellum (data not shown). At 12 months we
observed decrease of NAA (20 %, p\ 0.05) in both hip-
pocampus and cerebellum, which was clearly visible in the
spectra (Fig. 2). The increase in Ins noticed in the cere-
bellum at 6 months was also observed at 12 months (17 %,
p\ 0.05). This increase is also discernible in the spectra
presented in Fig. 2.
In the Prnp -/- mice at 6 months of age, the overall
neurochemical profile was similar to the WT in the hip-
pocampus and cerebellum (data not shown). However, at
12 months of age an increase of Glu (30 %, p\ 0.001), Ins
(20 %, p\ 0.01), and Lac (100 %, without reaching sta-
tistically significance) was found in the hippocampus
(Fig. 4). An increase of Lac (100 %, p\ 0.05) was also
observed in the cerebellum.
Discussion
To the best of our knowledge, this is the first study eval-
uating the neurochemical profile of transgenic mouse
models of prion disease. In the present study, the high
quality data obtained in vivo at 14.1 T was evident from
the high signal to noise ratio signal-to-noise ratio, excellent
↓
↓
↓
Fig. 2 SPECIAL 1H spectra (TE = 2.8 ms, TR = 4000 ms) and
voxel localization acquired at the age of 12 months in the hippocam-
pus and cerebellum of a WT and PrPD32-121 mouse. Differences in
relative intensities are visible in the spectra and marked with arrows
(i.e. decreased NAA and increased Ins peaks)
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water suppression, localization performance and spectral
resolution. In addition, the ultra-short echo time used
during our acquisitions (TE = 2.8 ms) combined with a
reliable quantification algorithm allowed the quantification
of 19 metabolites in the hippocampus and cerebellum of 6
and 12 months old Prnp -/- and PrPD32-121 mice and thus
substantial metabolic information was obtained in prion
disease.
In the mouse brain, 1H MRS can be technically rather
challenging due to its small size, especially if spectra are
acquired in a small brain region, which is, in addition,
located close to the interface between the diamagnetic
tissue and air containing paramagnetic oxygen. Moreover,
magnetic field inhomogeneities induced in the brain by the
difference in susceptibility on air/tissue interface are scaled
linearly with B0, thus leading to increased peak linewidths
(in Hz). In our study, the high quality of mouse brain
spectra was achieved due to shimming with FASTMAP
and also due to high signal intensity provided by the spin-
echo full intensity localization technique (SPECIAL) in a
scan time of 25 min. The water linewidths were compa-
rable with previously published mouse data [24, 25], with
slightly larger water linewidths in the cerebellum compared
to hippocampus. This is mainly due to the fact that the
WT
Prnp -/-
↓
↓
↓
Fig. 4 Representative 1H MRS spectra acquired in the hippocampus
of a WT and Prnp -/- mouse at 12 months of age using the SPECIAL
sequence (TE = 2.8 ms, TR = 4000 ms)
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Fig. 3 Neurochemical profile (mean ± SD) in the hippocampus (H) and cerebellum (C) of Prnp -/-, WT and PrPD32-121 mice at 12 months of age
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cerebellum has higher microscopic heterogeneity but also
due to its location (closer to the neck with a potentially
higher risk of movement).
To the best of our knowledge, very few 1H MRS studies
were performed in vivo on humans or mice models injected
with CJD (Creutzfeldt–Jakob) or scrapie agent (ME7
strain). All these previous studies were done at low mag-
netic field and only a few metabolites were measured (i.e.
NAA, tCr, tCho, and sometimes Ins) and mainly metabolite
ratios were reported and not absolute concentrations [7–
14]. These studies reported changes in Ins and NAA con-
centrations. The decrease of NAA was reported to reflect
neuronal stress and death whereas the increase of Ins an
indicator of astrogliosis.
Previously published studies on the Prnp -/- mice
showed that these mice develop and reproduce normally
and show no detectable physical or behavioral defect
together with no apparent immunological changes for at
least 7 months [4]. Moreover, when inoculated with mouse
scrapie prions they remain free of scrapie symptoms for
13 months in contrast to wild-type controls which died
after at 6 months of age [26], suggesting that PrPc is
required for the usual susceptibility to scrapie and that the
lack of homology between incoming prions and the host’s
PrP genes inhibits the disease. Phenotypic defects in these
knockout mice suggested a role of PrPc in maintaining
normal circadian rhythms, superoxide dismutase activity
and protection from oxidative stress and copper metabo-
lism [27–29]. More recent studies on mice lacking prion
protein prepared in another laboratory showed significant
age-related defects in motor coordination and balance
together with spongiform pathology and reactive astrocytic
gliosis on brain analysis which normally characterize prion
disease [3].
In addition to the previously mentioned studies, our
study characterized the brain metabolites in vivo and lon-
gitudinally in Prnp -/- mice using 1H MRS and reported the
concentration of 19 brain metabolites providing substantial
metabolic information. Among these metabolites only Glu,
and Ins showed significant changes in hippocampus at
12 months of age, whereas no changes being measured at
6 months of age.
Glutamate is an important amino acid present in the
brain at high concentrations (see Fig. 3) and a major
excitatory neurotransmitter [30]. Changes in glutamate
levels were linked to a dysfunction in the neurotransmis-
sion or to metabolic activity (Krebs cycle) with increases of
glutamate concentration being related to increased meta-
bolic activity [30]. In addition, we have computed the Gln/
Glu ratios and found a 30 % decrease compared with the
WT animals at 12 months of age. Brain glutamine is
exclusively synthesized in glial cells, through the glu-
tamine synthetase enzyme [31], from glutamate cleared
from the synaptic cleft, thus having a major role in neu-
rotransmission. Then this glutamine is shuttled to neurons
where it can be deaminated, completing the so-called
glutamate–glutamine cycle [32, 33]. Therefore, Gln/Glu
ratios may reflect glutamate–glutamine cycle activity
between neurons and glial cells.
The roles of Ins in the brain are not fully understood,
however, it is accepted to be a major osmolyte involved in
the maintenance of cell volume. It is also a constituent of
phosphoglycerides and consequently lipid component of
biomembranes and a major component of intracellular
second messenger system [30]. Reduced concentrations of
Ins have been linked to a response to an osmotic stress [34,
37] while increased concentrations, which appear to be
more specific for neurodegenerative diseases, were
believed to reflect increased population of glial cells based
on the hypothesis that Ins is expressed in high amounts in
glial cells [35]. Our findings of increased Ins in the hip-
pocampus at 12 months seems to be potentially linked to
astrogliosis, in agreement with the histological results
obtained previously on Prnp -/- mice [3] and on humans or
mice models injected with scrapie agent [7, 14]. To date,
the in vivo modifications in Glu and Lac concentrations
have never been reported in Prnp -/- mice.
On the other hand, PrPD32-121 mice were shown to
develop ataxia and neuronal death, which were limited to the
granular layer of the cerebellum, as early as in 1–3 months
old animals [5]. Our measurements showed that the most
important modifications in the brain metabolites appeared
mainly at 12 months of age in both hippocampus and
cerebellum (decreased NAA and increased Ins), even though
we also detected significant changes at 6 months of age in
these mice (increased Ins and Glu). The increase of Ins in
the cerebellum at 6 and 12 months may reflect astrogliosis
related to an inflammatory process, consistent with the his-
tological features [5]. Since the role of Ins as a glial marker
is sometimes disputed, we analyzed the linear correlation
with glutamine only at 12 months of age and detected a
linear relation with R2 = 0.6. Glutamine synthetase enzyme,
predominately located in astrocytes [31] although it may
also be expressed in neurons under certain pathological
conditions [30], is responsible for the synthesis of glutamine
from glutamate cleared from the synaptic cleft. Glutamine
synthetase is also the major pathway for ammonia detoxi-
fication [34, 36, 37].
NAA is found in high concentrations in the brain and is
generally considered as a neuronal marker based on pre-
vious studies showing that brain tumors of glial origin did
not contain NAA [30, 38]. Later on, NAA was also
localized in immature oligodendrocytes using cultured
cells [39]. From studies of neurodegenerative conditions,
NAA was suggested to be a marker of neuronal density
while others consider NAA more as a marker of neuronal
2644 Neurochem Res (2015) 40:2639–2646
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function since NAA was shown to recover following
stroke, mitochondrial disorders and multiple sclerosis [30,
40–42]. In our study, the decrease in NAA was shown to
appear at the end stage of the disease (i.e. in 12 months old
mice) and it seems to reflect neuronal loss in agreement
with the histological findings [5] and with the studies
performed post-mortem in humans. Since glutamate is
considered to be mainly located in neurons [32, 33] (even
though sometimes this assumption needs to be taken with
care [30]), we have plotted the linear correlation between
NAA and Glu at 12 months of age and found a good cor-
relation with R2 = 0.57.
Finally, when comparing the brain metabolites changes
measured in Prnp -/- mice to those in PrPD32-121 mice we can
notice that modifications were obtained mainly at 12 months
of age in both models with some modifications already
noticeable at 6 months of age only in the cerebellum of
PrPD32-121 mice (increase of Ins and Glu). Moreover, Prnp -/-
mice showed stronger modifications in the hippocampus
(increase of Ins and Glu) than in the cerebellum (increase of
Lac), while PrPD32-121 mice showed a decrease of NAA in
both brain regions and an increase of Ins only in the cere-
bellum. The increase in Ins observed in both mouse models
is consistent with the observations made in human prion
disease reflecting astrogliosis. From histological point of
view, while the Prnp -/- mice used in our study developed
normally with no sever pathology [4], the Prnp -/- mice
prepared in another laboratory showed very similar charac-
teristics to the human disease (i.e. age-related defects in
motor coordination and balance together with spongiform
pathology and reactive astrocytic gliosis in globus pallidus
and cerebellum [3]). The PrPD32-121 mice suffer from ataxia
and seem to have different pathology from prion infections
characterized by astrogliosis and cerebellar granule cell loss
mainly in the cerebellum [5], even thought our measure-
ments showed modifications which are very similar to the
human prion disease (decrease NAA in both hippocampus
and cerebellum and increased Ins in cerebellum). In addi-
tion, some recent transcriptomic analyses showed that there
is considerable overlap between the mice used in our study,
the exposure to antibodies targeting the cellular prion pro-
tein and the pathologies related to prions, namely prion
infections [43, 44].
We conclude that high-field MR spectroscopy allows to
analyze in detail the concentrations of 19 brain metabolites
in Prnp -/- and PrPD32-121 mice and consequently provides
additional information to the previous behavioral and his-
tological measurements.
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